NASDAQ:IDXX IDEXX Laboratories (IDXX) Stock Forecast, Price & News $453.00 +2.30 (+0.51%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$449.05▼$457.0050-Day Range$450.70▼$503.6152-Week Range$317.06▼$515.79Volume386,928 shsAverage Volume450,746 shsMarket Capitalization$37.55 billionP/E Ratio54.51Dividend YieldN/APrice Target$527.86 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability IDEXX Laboratories MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside16.5% Upside$527.86 Price TargetShort InterestBearish2.69% of Float Sold ShortDividend StrengthN/ASustainability-2.09Upright™ Environmental ScoreNews Sentiment0.78Based on 4 Articles This WeekInsider TradingSelling Shares$6.40 M Sold Last QuarterProj. Earnings Growth15.34%From $9.65 to $11.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.43 out of 5 starsMedical Sector188th out of 985 stocksDiagnostic Substances Industry5th out of 15 stocks 2.4 Analyst's Opinion Consensus RatingIDEXX Laboratories has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $527.86, IDEXX Laboratories has a forecasted upside of 16.5% from its current price of $453.00.Amount of Analyst CoverageIDEXX Laboratories has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.69% of the float of IDEXX Laboratories has been sold short.Short Interest Ratio / Days to CoverIDEXX Laboratories has a short interest ratio ("days to cover") of 5.8.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldIDEXX Laboratories does not currently pay a dividend.Dividend GrowthIDEXX Laboratories does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIDEXX Laboratories has received a 46.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Urine analyzers", "Biochemical assay kits", and "Veterinary laboratories for pets" products. See details.Environmental SustainabilityThe Environmental Impact score for IDEXX Laboratories is -2.09. Previous Next 2.7 News and Social Media Coverage News SentimentIDEXX Laboratories has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for IDEXX Laboratories this week, compared to 5 articles on an average week.Search InterestOnly 13 people have searched for IDXX on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.MarketBeat Follows5 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,402,047.00 in company stock.Percentage Held by InsidersOnly 2.11% of the stock of IDEXX Laboratories is held by insiders.Percentage Held by Institutions87.90% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for IDEXX Laboratories are expected to grow by 15.34% in the coming year, from $9.65 to $11.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEXX Laboratories is 54.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.83.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEXX Laboratories is 54.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 145.95.Price to Earnings Growth RatioIDEXX Laboratories has a PEG Ratio of 2.76. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIDEXX Laboratories has a P/B Ratio of 61.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IDEXX Laboratories (NASDAQ:IDXX) StockIDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, aRead More Receive IDXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address IDXX Stock News HeadlinesJune 7, 2023 | msn.comAtlantic Equities Reiterates Idexx Laboratories (IDXX) Prior RecommendationJune 7, 2023 | finance.yahoo.comIs Now The Time To Look At Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?June 9, 2023 | Vantage Point (Ad)Major Financial Crisis Could Hit AmericaSomething strange is happening in our financial system. UBS analysts predict over 50,000 retail locations may close soon. Retail giants like Walmart, Foot Locker, Bed Bath & Beyond, and Macy's are already downsizing their stores. Are you using the best technology to protect your money at all costs? June 6, 2023 | msn.com$1000 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth This Much TodayJune 1, 2023 | finance.yahoo.comIdexx (IDXX) Down 2.9% Since Last Earnings Report: Can It Rebound?June 1, 2023 | americanbankingnews.comBrokerages Set IDEXX Laboratories, Inc. (NASDAQ:IDXX) PT at $527.86May 29, 2023 | finance.yahoo.comHere’s Why IDEXX Laboratories (IDXX) Rose in Q1May 26, 2023 | fool.comIdexx Laboratories (NASDAQ: IDXX)June 9, 2023 | Vantage Point (Ad)Major Financial Crisis Could Hit AmericaSomething strange is happening in our financial system. UBS analysts predict over 50,000 retail locations may close soon. Retail giants like Walmart, Foot Locker, Bed Bath & Beyond, and Macy's are already downsizing their stores. Are you using the best technology to protect your money at all costs? May 25, 2023 | americanbankingnews.comIDEXX Laboratories (NASDAQ:IDXX) Trading Down 3.9% After Insider SellingMay 24, 2023 | americanbankingnews.comJonathan W. Ayers Sells 10,000 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) StockMay 22, 2023 | benzinga.comHere's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 15 YearsMay 17, 2023 | finance.yahoo.comInvesting in IDEXX Laboratories (NASDAQ:IDXX) five years ago would have delivered you a 146% gainMay 16, 2023 | msn.comIDEXX Laboratories' Debt OverviewMay 12, 2023 | msn.comIDEXX Laboratories Could Beat FY23 Guidance, But Valuation Is An IssueMay 10, 2023 | marketwatch.comIDEXX Laboratories Inc. stock rises Wednesday, outperforms marketMay 10, 2023 | finance.yahoo.comIDEXX Laboratories to Present at Stifel Conference and Announces 2023 Investor DayMay 9, 2023 | americanbankingnews.comIDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives $520.63 Average Price Target from AnalystsMay 8, 2023 | marketwatch.comIDEXX Laboratories Inc. stock underperforms Monday when compared to competitorsMay 8, 2023 | americanbankingnews.comInsider Selling: IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Sells $1,025,746.74 in StockMay 6, 2023 | finance.yahoo.comAt US$488, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?May 6, 2023 | seekingalpha.comIDEXX Laboratories Q1 Earnings: Strong Results But Hard To Justify The PriceMay 6, 2023 | americanbankingnews.comIDEXX Laboratories, Inc. Expected to Post Q2 2023 Earnings of $2.45 Per Share (NASDAQ:IDXX)May 5, 2023 | markets.businessinsider.comMorgan Stanley Sticks to Its Buy Rating for Idexx Laboratories (IDXX)May 5, 2023 | americanbankingnews.comIDEXX Laboratories, Inc. to Post FY2024 Earnings of $11.01 Per Share, William Blair Forecasts (NASDAQ:IDXX)May 3, 2023 | msn.comAtlantic Equities Reiterates Idexx Laboratories (IDXX) Overweight RecommendationMay 3, 2023 | markets.businessinsider.comIdexx Laboratories (IDXX) Gets a Buy from Goldman SachsSee More Headlines IDXX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDXX Company Calendar Last Earnings2/06/2023Today6/08/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:IDXX CUSIP45168D10 CIK874716 Webwww.idexx.com Phone(207) 556-0300Fax207-556-4346Employees10,780Year Founded1983Price Target and Rating Average Stock Price Forecast$527.86 High Stock Price Forecast$600.00 Low Stock Price Forecast$415.00 Forecasted Upside/Downside+16.5%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$8.31 Trailing P/E Ratio54.51 Forward P/E Ratio46.94 P/E Growth2.76Net Income$679.09 million Net Margins20.38% Pretax Margin25.83% Return on Equity117.37% Return on Assets25.89% Debt Debt-to-Equity Ratio0.83 Current Ratio1.08 Quick Ratio0.71 Sales & Book Value Annual Sales$3.37 billion Price / Sales11.15 Cash Flow$9.42 per share Price / Cash Flow48.11 Book Value$7.35 per share Price / Book61.63Miscellaneous Outstanding Shares82,900,000Free Float81,151,000Market Cap$37.55 billion OptionableOptionable Beta1.19 Social Links Key ExecutivesJonathan J. MazelskyPresident, Chief Executive Officer & DirectorJohn HartSenior Vice President-Global OperationsBrian Patrick McKeonChief Financial Officer, Treasurer & Executive VPKen GradyChief Information Officer & Senior VPMurthy YerramilliSenior Vice President-Research & DevelopmentKey CompetitorsHaleonNYSE:HLNGE HealthCare TechnologiesNASDAQ:GEHCAlconNYSE:ALCSeagenNASDAQ:SGENCenteneNYSE:CNCView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCSold 3,195 shares on 6/1/2023Ownership: 0.001%Coastline Trust CoBought 470 shares on 5/31/2023Ownership: 0.001%BKA Wealth Consulting Inc.Bought 417 shares on 5/30/2023Ownership: 0.001%ProShare Advisors LLCBought 29,204 shares on 5/26/2023Ownership: 0.127%Empower Advisory Group LLCBought 891 shares on 5/25/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions IDXX Stock - Frequently Asked Questions Should I buy or sell IDEXX Laboratories stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDXX shares. View IDXX analyst ratings or view top-rated stocks. What is IDEXX Laboratories' stock price forecast for 2023? 7 equities research analysts have issued 12-month price objectives for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $600.00. On average, they expect the company's stock price to reach $527.86 in the next twelve months. This suggests a possible upside of 16.5% from the stock's current price. View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts. How have IDXX shares performed in 2023? IDEXX Laboratories' stock was trading at $407.96 on January 1st, 2023. Since then, IDXX stock has increased by 11.0% and is now trading at $453.00. View the best growth stocks for 2023 here. When is IDEXX Laboratories' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our IDXX earnings forecast. How were IDEXX Laboratories' earnings last quarter? IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings results on Monday, February, 6th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.13. The company had revenue of $828.60 million for the quarter, compared to analysts' expectations of $820.91 million. IDEXX Laboratories had a net margin of 20.38% and a trailing twelve-month return on equity of 117.37%. The firm's revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.89 EPS. Read the conference call transcript. What ETFs hold IDEXX Laboratories' stock? ETFs with the largest weight of IDEXX Laboratories (NASDAQ:IDXX) stock in their portfolio include ProShares Pet Care ETF (PAWZ), Sterling Capital Focus Equity ETF (LCG), First Trust Water ETF (FIW), Invesco DWA Healthcare Momentum ETF (PTH), Neuberger Berman Disrupters ETF (NBDS), iShares U.S. Medical Devices ETF (IHI), Simplify Health Care ETF (PINK) and QRAFT AI-Enhanced U.S. Large Cap ETF (QRFT). What guidance has IDEXX Laboratories issued on next quarter's earnings? IDEXX Laboratories issued an update on its FY23 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share (EPS) guidance of $9.33-$9.75 for the period, compared to the consensus estimate of $9.63. The company issued revenue guidance of $3.619-$3.70 billion, compared to the consensus revenue estimate of $3.66 billion. What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO? 40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees. What other stocks do shareholders of IDEXX Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP). What is IDEXX Laboratories' stock symbol? IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX." Who are IDEXX Laboratories' major shareholders? IDEXX Laboratories' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.49%), State Street Corp (4.43%), Geode Capital Management LLC (2.35%), Franklin Resources Inc. (1.63%), Blair William & Co. IL (1.46%) and Brown Advisory Inc. (1.38%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek. View institutional ownership trends. How do I buy shares of IDEXX Laboratories? Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IDEXX Laboratories' stock price today? One share of IDXX stock can currently be purchased for approximately $453.00. How much money does IDEXX Laboratories make? IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $37.55 billion and generates $3.37 billion in revenue each year. The company earns $679.09 million in net income (profit) each year or $8.31 on an earnings per share basis. How many employees does IDEXX Laboratories have? The company employs 10,780 workers across the globe. How can I contact IDEXX Laboratories? IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346. This page (NASDAQ:IDXX) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEXX Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.